Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid injection for primary osteoporosis and osteoporotic fracture
ChiCTR2000034692Phase 4Recruiting
- Sponsor
- Chizhou People's Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in involutional osteoporosis and fragility fracture, sponsored by Chizhou People's Hospital. Primary endpoints: Lumbar spine bone mineral density at 6 months and Total hip and femoral neck bone mineral density at 6 months. Started Aug 2020; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
involutional osteoporosisfragility fracture
Beyond the preview
Go deeper on ChiCTR2000034692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034692.